News
Important Only
EXCLUSIVE-Tesla executives questioned Musk after he denied killing $25,000 EV project, sources say
Musk had already canceled the so-called Model 2 despite public denial, executives saidSome Tesla executives expressed concern Musk was deceiving investors about a low-cost EVTesla now plans more affordable, stripped-down versions of the Model 3 and Model YBy Rachael Levy June 2 (Reuters) - Some s...Reuters
Mon, Jun 2
MultiStrat adds Tompkins as executive director of capital markets
By David BullJune 2 - (The Insurer) - MultiStrat has hired former Securis Investment Partners and Towers Watson Investment Services (TWIS) executive Weston Tompkins to lead its MultiStrat Advisors unit.In his new role as executive director for capital markets, Tompkins will oversee and manage the Be...Reuters
Mon, Jun 2
JPMorgan CEO Jamie Dimon tells Fox Business US debt could cause bond turmoil
By Suzanne McGee and Nupur AnandNEW YORK, June 2 (Reuters) - JPMorgan Chase JPM.N CEO Jamie Dimon said on Monday that the rising U.S. national debt is a "big deal" that could create a "tough time" for the bond market that causes spreads to widen, he told Fox Business’ "Mornings w...Reuters
Mon, Jun 2
Guardant Health Announced the results of the Serena-6 Phase III Trial
June 2 (Reuters) - Guardant Health Inc GH.O:SERENA-6 PHASE III TRIAL DEMONSTRATES CLINICAL VALUE OF GUARDANT360 CDX TEST TO DETECT EMERGENCE OF ENDOCRINE RESISTANCE AND INFORM A SWITCH IN THERAPY BEFORE RADIOLOGICAL DISEASE PROGRESSION IN ADVANCED BREAST CANCERReuters
Mon, Jun 2
Safe & Green Holdings Signs Letter Of Intent To Acquire Giant Containers
June 2 (Reuters) - Safe & Green Holdings Corp SGBX.O:SAFE & GREEN HOLDINGS CORP. SIGNS LETTER OF INTENT TO ACQUIRE GIANT CONTAINERS INC.SAFE & GREEN HOLDINGS CORP: DEAL INCLUDES APPOINTMENT OF GIANT'S CEO, DANIEL KROFT, AS VP OF BUSINESS DEVELOPMENT AT SAFE & GREENReuters
Mon, Jun 2
Versabank expected to post earnings of 31 cents a share - Earnings Preview
Versabank VBNK.TO is expected to show a rise in quarterly revenue when it reports results on June 4 for the period ending April 30 2025The London Ontario-based company is expected to report a 6.3% increase in revenue to C$27.904 million from C$26.24 million a year ago, according to the mean estim...Reuters
Mon, Jun 2
Vistagen On Track To Deliver Topline Data From Fasedienol Palisade-3 Phase 3 Trial
June 2 (Reuters) - VistaGen Therapeutics Inc VTGN.O:VISTAGEN ON TRACK TO DELIVER TOPLINE DATA FROM FASEDIENOL PALISADE-3 PHASE 3 TRIAL FOR ACUTE TREATMENT OF SOCIAL ANXIETY DISORDER IN THE FOURTH QUARTER OF THIS YEARVISTAGEN THERAPEUTICS INC - PALISADE-4 PHASE 3 TRIAL RESULTS EXPECTED IN FIRST HALF ...Reuters
Mon, Jun 2
